EGFR and lung carcinoma: The discovery of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), however, has dramatically changed treatment strategies for EGFR-mutant non-small-cell lung cancer (NSCLC) patients and significantly improved progression-free survival (PFS) and overall survival (OS) compared with conventional chemotherapy.1–4 Likewise, the treatment outcome of BMs from lung cancers has also changed following this paradigm shift.